Insecticides (India) Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
INSECTICID · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Insecticides (India) Limited submitted its unaudited financial results for the quarter ended June 30, 2025 (Q1 FY26). Standalone revenue from operations rose about 31% year-on-year to ₹85,914.51 lacs from ₹65,668.53 lacs, while consolidated revenue grew about 35% to ₹88,358.31 lacs from ₹65,587.03 lacs. However, standalone profit after tax (PAT) fell sharply to ₹1,702.49 lacs from ₹4,913.59 lacs in Q1 FY25, a drop of roughly 65%, as total expenses climbed faster than revenue. Standalone EPS declined to ₹4.82 from ₹16.60. Joint statutory auditors S S Kothari Mehta & Co. LLP and Devesh Parekh & Co. issued an unqualified limited review report. Prior period consolidated figures have been restated following the acquisition of Kaeros Research Limited as a wholly owned subsidiary, accounted as a common control transaction under Ind AS 103.
The strong top-line growth is encouraging, but the steep fall in standalone profit despite higher sales signals serious margin pressure, likely from rising input costs in the agrochemical business. Shareholders should monitor whether margin compression eases in upcoming quarters before viewing the revenue growth as fully value-accretive.